Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ 1 34.5 deleted oncolytic herpes virus (G207) 1 JOSEPH J. BENNETT * , PRASAD ADUSUMILLI * , HENRIK PETROWSKY * , BRYAN M. BURT * , GRETCHEN ROBERTS * , KEITH A DELMAN * , JONATHAN S. ZAGER * , TING-CHAO CHOU† and YUMAN FONG * ,2 * Department of Surgery and 2 Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA 2 Correspondence: Hepatobiliary Division, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA. E-mail: fongy@mskcc.org <h3>SPECIFIC AIMS</h3> <h3>1. Determine whether oncolytic herpes viral therapy is synergistic with chemotherapy in treatment of gastric cancer</h3> Oncolytic herpes simplex viral therapy is a promising experimental cancer treatment that exploits the ability of genetically engineered HSV to specifically infect, replicate within, and kill tumor cells. The current study seeks to determine in vitro and in vivo whether the oncolytic virus G207 is synergistic with the alkylating agent mitomycin C in treatment of human gastric cancer cells, a tumor highly resistant to standard therapies. <h3>2. Examine the mechanistic basis of such synergy</h3> One strategy for genetically
/lp/fed-of-american-socs-for-experimental-biology/up-regulation-of-gadd34-mediates-the-synergistic-anticancer-activity-0xJ3PEIdqd